Do analysts rate TNGX or CVAC?

Tango Therapeutics currently has a consensus target price of $43.46, indicating a potential upside of 90.96%. Given Tango Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Tango Therapeutics is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tango Therapeutics 1 Sell rating(s) 2 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.75 CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, TNGX or CVAC?

CureVac has higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tango Therapeutics $62.38M 61.52 -$101.59M -$0.85 N/A CureVac $70.74M 14.78 $175.50M $0.72 6.47

Do analysts recommend CVAC or AMLX?

Amylyx Pharmaceuticals has a consensus price target of $36.50, indicating a potential upside of 7.48%. Given Amylyx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Amylyx Pharmaceuticals is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Amylyx Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.00

Do analysts recommend DNLI or CVAC?

Denali Therapeutics presently has a consensus target price of $35.85, suggesting a potential upside of 57.22%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Denali Therapeutics is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Denali Therapeutics 1 Sell rating(s) 2 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.76 CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer CVAC or VKTX?

Viking Therapeutics has a consensus price target of $96.63, suggesting a potential upside of 184.36%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Viking Therapeutics is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Viking Therapeutics 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.75

Do analysts prefer CVAC or LEGN?

Legend Biotech has a consensus target price of $52.29, indicating a potential upside of 140.39%. Given Legend Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Legend Biotech is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Legend Biotech 1 Sell rating(s) 6 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.47

CureVac (CVAC) Competitors

$4.66 0.00 (0.00%)

As of 09/2/2026

Compare

CVAC vs. TNGX, AMLX, DNLI, VKTX, and LEGN

Should you buy CureVac stock or one of its competitors? CureVac's main competitors and comparable companies include Tango Therapeutics (TNGX), Amylyx Pharmaceuticals (AMLX), Denali Therapeutics (DNLI), Viking Therapeutics (VKTX), and Legend Biotech (LEGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does CureVac compare to Tango Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and CureVac (NASDAQ:CVAC) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.

Tango Therapeutics currently has a consensus target price of $43.46, indicating a potential upside of 90.96%. Given Tango Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Tango Therapeutics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Tango Therapeutics had 10 more articles in the media than CureVac. MarketBeat recorded 10 mentions for Tango Therapeutics and 0 mentions for CureVac. Tango Therapeutics' average media sentiment score of 1.27 beat CureVac's score of 0.00 indicating that Tango Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Tango Therapeutics	Positive
CureVac	Neutral

79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 6.5% of Tango Therapeutics shares are owned by insiders. Comparatively, 2.2% of CureVac shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

CureVac has higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	61.52	-$101.59M	-$0.85	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

CureVac has a net margin of 199.92% compared to Tango Therapeutics' net margin of 0.00%. CureVac's return on equity of -23.03% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-25.75%	-23.36%
CureVac	199.92%	-23.03%	-19.09%

Tango Therapeutics has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market. Comparatively, CureVac has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market.

Summary

Tango Therapeutics and CureVac tied by winning 8 of the 16 factors compared between the two stocks.

How does CureVac compare to Amylyx Pharmaceuticals?

CureVac (NASDAQ:CVAC) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

17.3% of CureVac shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 2.2% of CureVac shares are owned by company insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Amylyx Pharmaceuticals had 4 more articles in the media than CureVac. MarketBeat recorded 4 mentions for Amylyx Pharmaceuticals and 0 mentions for CureVac. Amylyx Pharmaceuticals' average media sentiment score of 1.31 beat CureVac's score of 0.00 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
CureVac	Neutral
Amylyx Pharmaceuticals	Positive

CureVac has a net margin of 199.92% compared to Amylyx Pharmaceuticals' net margin of 0.00%. CureVac's return on equity of -23.03% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%

CureVac has higher earnings, but lower revenue than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Amylyx Pharmaceuticals	$87.37M	43.31	-$144.74M	-$1.43	N/A

CureVac has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.13, meaning that its share price is 113% less volatile than the broader market.

Amylyx Pharmaceuticals has a consensus price target of $36.50, indicating a potential upside of 7.48%. Given Amylyx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Amylyx Pharmaceuticals is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Amylyx Pharmaceuticals beats CureVac on 10 of the 17 factors compared between the two stocks.

How does CureVac compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and CureVac (NASDAQ:CVAC) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends.

CureVac has a net margin of 199.92% compared to Denali Therapeutics' net margin of 0.00%. CureVac's return on equity of -23.03% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-55.27%	-44.24%
CureVac	199.92%	-23.03%	-19.09%

CureVac has lower revenue, but higher earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	11.03	-$512.54M	-$2.84	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

Denali Therapeutics has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market. Comparatively, CureVac has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market.

In the previous week, Denali Therapeutics had 9 more articles in the media than CureVac. MarketBeat recorded 9 mentions for Denali Therapeutics and 0 mentions for CureVac. Denali Therapeutics' average media sentiment score of 1.46 beat CureVac's score of 0.00 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Denali Therapeutics	Positive
CureVac	Neutral

92.9% of Denali Therapeutics shares are held by institutional investors. Comparatively, 17.3% of CureVac shares are held by institutional investors. 9.7% of Denali Therapeutics shares are held by company insiders. Comparatively, 2.2% of CureVac shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Denali Therapeutics presently has a consensus target price of $35.85, suggesting a potential upside of 57.22%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Denali Therapeutics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Denali Therapeutics and CureVac tied by winning 8 of the 16 factors compared between the two stocks.

How does CureVac compare to Viking Therapeutics?

CureVac (NASDAQ:CVAC) and Viking Therapeutics (NASDAQ:VKTX) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

CureVac has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A

CureVac has a net margin of 199.92% compared to Viking Therapeutics' net margin of 0.00%. CureVac's return on equity of -23.03% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Viking Therapeutics	N/A	-94.56%	-82.75%

17.3% of CureVac shares are held by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are held by institutional investors. 2.2% of CureVac shares are held by insiders. Comparatively, 5.3% of Viking Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Viking Therapeutics has a consensus price target of $96.63, suggesting a potential upside of 184.36%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Viking Therapeutics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Viking Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

CureVac has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market.

In the previous week, Viking Therapeutics had 11 more articles in the media than CureVac. MarketBeat recorded 11 mentions for Viking Therapeutics and 0 mentions for CureVac. Viking Therapeutics' average media sentiment score of 0.74 beat CureVac's score of 0.00 indicating that Viking Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
CureVac	Neutral
Viking Therapeutics	Positive

Summary

CureVac and Viking Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does CureVac compare to Legend Biotech?

CureVac (NASDAQ:CVAC) and Legend Biotech (NASDAQ:LEGN) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

17.3% of CureVac shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 2.2% of CureVac shares are owned by insiders. Comparatively, 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

CureVac has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market.

CureVac has a net margin of 199.92% compared to Legend Biotech's net margin of -7.21%. Legend Biotech's return on equity of -8.71% beat CureVac's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Legend Biotech	-7.21%	-8.71%	-5.40%

CureVac has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Legend Biotech	$1.03B	4.10	-$296.80M	-$0.25	N/A

Legend Biotech has a consensus target price of $52.29, indicating a potential upside of 140.39%. Given Legend Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Legend Biotech is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Legend Biotech	1 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.47

In the previous week, Legend Biotech had 6 more articles in the media than CureVac. MarketBeat recorded 6 mentions for Legend Biotech and 0 mentions for CureVac. Legend Biotech's average media sentiment score of 0.77 beat CureVac's score of 0.00 indicating that Legend Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
CureVac	Neutral
Legend Biotech	Positive

Summary

Legend Biotech beats CureVac on 9 of the 16 factors compared between the two stocks.

Get CureVac News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CVAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CVAC vs. The Competition

Export

Metric	CureVac	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.05B	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	6.47	12.66	273.28	25.38
Price / Sales	14.78	1,309.16	613.48	92.60
Price / Cash	4.73	106.87	77.82	52.26
Price / Book	1.39	16.29	12.89	6.14
Net Income	$175.50M	-$22.72M	$3.47B	$349.01M
7 Day Performance	N/A	0.34%	0.61%	-0.27%
1 Month Performance	N/A	8.52%	5.73%	0.68%
1 Year Performance	-12.90%	52.66%	25.37%	14.84%

CureVac Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CVAC CureVac	N/A	$4.66 flat	N/A	N/A	$1.05B	$70.74M	6.47	880
TNGX Tango Therapeutics	3.172 of 5 stars	$24.63 +0.5%	$43.46 +76.5%	+239.7%	$4.16B	$53.81M	N/A	90	Positive News
AMLX Amylyx Pharmaceuticals	2.2831 of 5 stars	$37.04 -2.9%	$36.25 -2.1%	+245.1%	$4.14B	N/A	N/A	200
DNLI Denali Therapeutics	3.2936 of 5 stars	$24.95 +3.1%	$35.92 +44.0%	+48.9%	$3.99B	$330.53M	N/A	430	News Coverage Positive News
VKTX Viking Therapeutics	2.9089 of 5 stars	$34.16 +2.8%	$96.63 +182.9%	+26.6%	$3.98B	N/A	N/A	20	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CVAC) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CureVac (CVAC) Competitors

CVAC vs. TNGX, AMLX, DNLI, VKTX, and LEGN

How does CureVac compare to Tango Therapeutics?

Summary

How does CureVac compare to Amylyx Pharmaceuticals?

Summary

How does CureVac compare to Denali Therapeutics?

Summary

How does CureVac compare to Viking Therapeutics?

Summary

How does CureVac compare to Legend Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVAC vs. The Competition

CureVac Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CureVac (CVAC) Competitors

CVAC vs. TNGX, AMLX, DNLI, VKTX, and LEGN

How does CureVac compare to Tango Therapeutics?

Do analysts rate TNGX or CVAC?

Does the media prefer TNGX or CVAC?

Do insiders and institutionals have more ownership in TNGX or CVAC?

Which has preferable valuation and earnings, TNGX or CVAC?

Is TNGX or CVAC more profitable?

Which has more risk and volatility, TNGX or CVAC?

Summary

How does CureVac compare to Amylyx Pharmaceuticals?

Do insiders & institutionals have more ownership in CVAC or AMLX?

Does the media refer more to CVAC or AMLX?

Is CVAC or AMLX more profitable?

Which has preferable earnings and valuation, CVAC or AMLX?

Which has more risk and volatility, CVAC or AMLX?

Do analysts recommend CVAC or AMLX?

Summary

How does CureVac compare to Denali Therapeutics?

Is DNLI or CVAC more profitable?

Which has higher earnings & valuation, DNLI or CVAC?

Which has more volatility and risk, DNLI or CVAC?

Does the media favor DNLI or CVAC?

Do institutionals and insiders hold more shares of DNLI or CVAC?

Do analysts recommend DNLI or CVAC?

Summary

How does CureVac compare to Viking Therapeutics?

Which has preferable valuation & earnings, CVAC or VKTX?

Is CVAC or VKTX more profitable?

Do institutionals & insiders hold more shares of CVAC or VKTX?

Do analysts prefer CVAC or VKTX?

Which has more risk & volatility, CVAC or VKTX?

Does the media favor CVAC or VKTX?

Summary

How does CureVac compare to Legend Biotech?

Do institutionals and insiders believe in CVAC or LEGN?

Which has more risk and volatility, CVAC or LEGN?

Is CVAC or LEGN more profitable?

Which has better valuation & earnings, CVAC or LEGN?

Do analysts prefer CVAC or LEGN?

Does the media favor CVAC or LEGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVAC vs. The Competition

CureVac Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools